Gilgamesh Pharmaceuticals
PrivateLast Round
Series A
Mar 24, 2026
Est. Valuation
$1.79M
Total Funding Raised
$140.13M
Company Overview
Gilgamesh Pharmaceuticals is a biotechnology company that specializes in creating innovative compounds to treat neurological disorders through a unique platform focused on mental health science.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Mental Health, Medical AI
Business Model
B2B
Customer Profile
Revenue Share, Services & Consulting, Government Contracts
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Gilgamesh Pharmaceuticals Comps
Public and private peers based on sector, stage, and business model.
Gilgamesh Pharmaceuticals Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Mar 24, 2026 | ||||
| Grant | Mar 14, 2024 | ||||
| Series B | Dec 15, 2022 | ||||
| Series A | May 6, 2021 | ||||
| Accelerator | Aug 24, 2020 |
Gilgamesh Pharmaceuticals Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Noetic Psychedelic Fund LP | Series A |
| Negev Capital | Series B |
| Route 66 Ventures | Series A, Series B |
| Gron Ventures | Series A, Series B |
| Y Combinator | Accelerator |
| Prime Movers Lab | Series A, Series B |
| Satori Capital | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 19, 2026
GM-3009, a novel ibogaine derivative for PTSD, is in early-stage clinical testing.
- Mar 24, 2026
$60M round completed.
Gilgamesh Pharmaceuticals Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Gilgamesh Pharmaceuticals's valuation, stock price, and market status.
